Jai Won Chang

Jai Won Chang

Auto-generated profile, based on publicly available information

Jai Won Chang

Division of Nephrology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2017 in Nutrients
Verified
Journal Article
Open access
PDF file
SKShin Sook Kang
Shin Sook Kang
JCJai Won Chang
Jai Won Chang
YPYongsoon Park
Yongsoon Park
Protein-energy wasting (PEW) is associated with mortality in patients with end-stage renal disease (ESRD) on maintenance hemodialysis. The correct diagnosis of PEW is extremely important in order to predict clinical outcomes. However, it is unclear which parameters should be used to diagnose PEW. Therefore, this retrospective observational study investigated the relationship between mortality and nutritional parameters in ESRD patients on maintenance hemodialysis. A total of 144 patients were enrolled. Nutritional parameters, including body mass index, serum albumin, dietary intake, normalized protein catabolic rate (nPCR), and malnutrition inflammation score (MIS), were measured at baseline. Fifty-three patients died during the study. Survivors had significantly higher nPCR (1.10 ± 0.24 g/kg/day vs. 1.01 ± 0.21 g/kg/day; p = 0.048), energy intake (26.7 ± 5.8 kcal/kg vs. 24.3 ± 4.2 kcal/kg; p = 0.009) and protein intake (0.91 ± 0.21 g/kg vs. 0.82 ± 0.24 g/kg; p = 0.020), and lower MIS (5.2 ± 2.3 vs. 6.1 ± 2.1, p = 0.039). In multivariable analysis, energy intake 5 (HR 2.146, 95% CI 1.173–3.928; p = 0.013) were independent variables associated with all-cause mortality. These results suggest that higher MIS and lower energy intake are harmful to ESRD patients on maintenance hemodialysis. Optimal energy intake could reduce mortality in these patients.

1 October 2023 in Clinical and Molecular Hepatology
Verified
Journal Article
Open access
PDF file
CJChan-Young Jung
Chan-Young Jung
JCJai Won Chang
Jai Won Chang
Hepatorenal syndrome (HRS), a progressive but potentially reversible deterioration of kidney function, remains a major complication in patients with advanced cirrhosis, often leading to death before liver transplantation (LT). Recent updates in the pathophysiology, definition, and classification of HRS have led to a complete revision of the nomenclature and diagnostic criteria for HRS type 1, which was renamed HRS-acute kidney injury (AKI). HRS is characterized by severe impairment of kidney function due to increased splanchnic blood flow, activation of several vasoconstriction factors, severe vasoconstriction of the renal arteries in the absence of kidney histologic abnormalities, nitric oxide dysfunction, and systemic inflammation. Diagnosis of HRS remains a challenge because of the lack of specific diagnostic biomarkers that accurately distinguishes structural from functional AKI, and mainly involves the differential diagnosis from other forms of AKI, particularly acute tubular necrosis. The optimal treatment of HRS is LT. While awaiting LT, treatment options include vasoconstrictor drugs to counteract splanchnic arterial vasodilation and plasma volume expansion by intravenous albumin infusion. In patients with HRS unresponsive to pharmacological treatment and with conventional indications for kidney replacement therapy (KRT), such as volume overload, uremia, or electrolyte imbalances, KRT may be applied as a bridging therapy to transplantation. Other interventions, such as transjugular intrahepatic portosystemic shunt, and artificial liver support systems have a very limited role in improving outcomes in HRS. Although recently developed novel therapies have potential to improve outcomes of patients with HRS, further studies are warranted to validate the efficacy of these novel agents.

Verified
Journal Article
Open access
PDF file
HKHyosang Kim
Hyosang Kim
CBChung Hee Baek
Chung Hee Baek
RLRaymond Bok Lee
Raymond Bok Lee
JCJai Won Chang
Jai Won Chang
WYWon Seok Yang
Won Seok Yang
SLSang Koo Lee
Sang Koo Lee
Endoplasmic reticulum (ER) stress is increasingly identified as modulator of fibrosis. Losartan, an angiotensin II receptor blocker, has been widely used as the first choice of treatment in chronic renal diseases. We postulated that anti-fibrotic effect of losartan is mediated through inhibition of ER stress via SIRT1 (silent mating type information regulation 2 homolog 1) hemeoxygenase-1 (HO-1)/thioredoxin pathway. Renal tubular cells, tunicamycin (TM)-induced ER stress, and unilateral ureteral obstruction (UUO) mouse model were used. Expression of ER stress was assessed by Western blot analysis and immunohistochemical stain. ER stress was induced by chemical ER stress inducer, tunicamycin, and non-chemical inducers such as TGF-β, angiotensin II, high glucose, and albumin. Losartan suppressed the TM-induced ER stress, as shown by inhibition of TM-induced expression of GRP78 (glucose related protein 78) and p-eIF2α (phosphospecific-eukaryotic translation initiation factor-2α), through up-regulation of SIRT1 via HO-1 and thioredoxin. Losartan also suppressed the ER stress by non-chemical inducers. In both animal models, losartan reduced the tubular expression of GRP78, which were abolished by pretreatment with sirtinol (SIRT1 inhibitor). Sirtinol also blocked the inhibitory effect of losartan on the UUO-induced renal fibrosis. These findings provide new insights into renoprotective effects of losartan and suggest that SIRT1, HO-1, and thioredoxin may be potential pharmacological targets in kidney diseases under excessive ER stress condition.

1 December 2011 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
KPKyung Sun Park
Kyung Sun Park
JCJai Won Chang
Jai Won Chang
TKTae Young Kim
Tae Young Kim
HKHyun Woo Kim
Hyun Woo Kim
ELEun Kyoung Lee
Eun Kyoung Lee
JPJung Sik Park
Jung Sik Park
Background: Serum phosphorus concentrations are associated with an increased risk of cardiovascular disease (CVD) and mortality in patients with rena

1 July 2017 in Transplantation Proceedings
Verified
Journal Article
Closed access
SBS.D. Baek
S.D. Baek
MJM. Jang
M. Jang
WKW. Kim
W. Kim
HYH. Yu
H. Yu
SHS. Hwang
S. Hwang
JCJ.W. Chang
J.W. Chang

1 November 2019 in Medicine
Verified
Journal Article
Open access
SJSeonJeong Jeong
SeonJeong Jeong
HKHyunwook Kwon
Hyunwook Kwon
JCJai Won Chang
Jai Won Chang
MKMin-Ju Kim
Min-Ju Kim
KGKhaliun Ganbold
Khaliun Ganbold
YCYong-Pil Cho
Yong-Pil Cho
This study compared clinical outcomes of patient survival and arteriovenous fistula (AVF) patency between incident hemodialysis patients with and without type 2 diabetes mellitus (T2DM). Between January 2011 and December 2013, 384 consecutive incident hemodialysis patients with confirmed first upper-extremity AVF placement were divided into a T2DM group (n = 180, 46.9%) and a non-DM group (n = 204, 53.1%) and analyzed retrospectively. The primary outcome was all-cause mortality, and secondary outcome was AVF patency. Patients in the T2DM group had a higher prevalence of hypertension (P = .02), smoking (P < .01), cardiovascular disease (P < .01), history of cerebrovascular accident (CVA) (P < .01), and peripheral arterial occlusive disease (P < .01) than those in the non-DM group. On Kaplan–Meier survival analysis, the overall survival and AVF patency rates were significantly higher in the non-DM group relative to the T2DM group (both P < .01). In the adjusted model, older age (hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.02–1.06; P < .01), T2DM (HR, 1.76; 95% CI, 1.12–2.77; P = .014), and history of CVA (HR, 1.76; 95% CI, 1.04–2.98; P = .04) were significantly associated with an increased risk of mortality. Older age and T2DM were independently associated with decreased primary (HR, 1.03; 95% CI, 1.02–1.04; P < .01, HR, 1.69; 95% CI, 1.22–2.33; P < .01, respectively) and secondary (HR, 1.03; 95% CI, 1.01–1.04; P < .01, HR, 2.07; 95% CI, 1.42–3.00; P < .01, respectively) AVF patency during follow-up. Compared with patients in the non-DM group, patients in the T2DM group had a higher mortality rate and worse AVF patency rates.